Oseltamivir

Generic Name: Oseltamivir

Brand Names: Ebilfumin, Tamiflu

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₂₈N_₂O_₄

CAS Number: 196618-13-0

Unique Ingredient Identifier: 20O93L6F9H

Background: Oseltamivir (marketed as the product TamifluⓇ), is an antiviral neuraminidase inhibitor used for the treatment and prophylaxis of infection with influenza viruses A (including pandemic H1N1) and B. Oseltamivir exerts its antiviral activity by inhibiting the activity of the viral neuraminidase enzyme found on the surface of the virus, which prevents budding f...

Indication: According to FDA prescribing information, oseltamivir is indicated for the treatment of acute, uncomplicated illness due to influenza A and B infection in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours . In particular, this agent is indicated in adults and children including full-term neonates who present with symptoms ...

Associated Conditions: Flu caused by Influenza, Influenza A Virus Infection, Influenza A, Influenza B, Influenza Type B

Associated Therapies: -

Clinical Trials

A Multicenter Randomized Open-label Study of Oseltamivir Combined With HD-DEX Versus HD-DEX in the Management of ITP

Phase 2

Completed

Conditions: Thrombocytopenia

Interventions: Drug: Oseltamivir
Drug: Dexamethasone

First Posted Date: 2013-10-18

Last Posted Date: 2020-08-25

Lead Sponsor: Shandong University

Target Recruit Count: 96

Registration Number: NCT01965626

Locations: 🇨🇳
Qilu hospital, Shandong University, Jinan, Shandong, China

Comparative Clinical Trial of Efficacy and Safety of Ergoferon Versus Oseltamivir in Treatment of Influenza

Phase 4

Completed

Conditions: Influenza

Interventions: Drug: Ergoferon
Drug: Oseltamivir

First Posted Date: 2013-05-09

Last Posted Date: 2020-04-16

Lead Sponsor: Materia Medica Holding

Target Recruit Count: 184

Registration Number: NCT01850446

Locations: 🇷🇺
Regional State Budgetary Healthcare Institution "Clinical Hospital №1", Smolensk, Russian Federation
🇷🇺
Pirogov Russian National Research Medical University, Moscow, Russian Federation
🇷🇺
St. Petersburg State Budgetary Health Care Institution " City policlinic No. 117", St. Petersburg, Russian Federation

and more 4 locations

Clinical Trial of Clinical Efficiency and Safety of Ergoferon in Treatment of Influenza

Phase 4

Completed

Conditions: Influenza

Interventions: Drug: Ergoferon
Drug: Oseltamivir

First Posted Date: 2013-03-05

Last Posted Date: 2015-06-23

Lead Sponsor: Materia Medica Holding

Target Recruit Count: 161

Registration Number: NCT01804946

Locations: 🇷🇺
St. Petersburg State Budgetary Health Care Institution "Сity Polyclinic № 117", St. Petersburg, Russian Federation
🇷🇺
State Budgetary Educational Institution of Higher Professional Education "Smolensk State Medical Academy" of Ministry of Health and Social Development of Russian Federation, Smolensk, Russian Federation
🇷🇺
St. Petersburg State Budgetary Health Care Institution "City Polyclinic №106", St. Petersburg, Russian Federation

and more 5 locations

A Pharmacokinetic/Pharmacodynamic Study of Oseltamivir in Immunocompromised Children With Confirmed Influenza Infection

Phase 1

Completed

Conditions: Influenza

Interventions: Drug: Oseltamivir

First Posted Date: 2012-10-29

Last Posted Date: 2018-10-16

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 20

Registration Number: NCT01715909

Locations: 🇺🇸
Lucile Packard Child Hosp; Pediatric Pulmonary Division, Palo Alto, California, United States
🇧🇪
Cliniques Universitaires St-Luc, Bruxelles, Belgium
🇧🇷
Hospital São Lucas da PUCRS, Porto Alegre, RS, Brazil

and more 47 locations

Alcohol Inhibits Drug Metabolism by Carboxylesterases

Phase 1

Completed

Conditions: Drug Interactions

Interventions: Drug: Placebo
Drug: Ethanol
Drug: Aspirin
Drug: Oseltamivir

First Posted Date: 2012-10-16

Last Posted Date: 2012-10-16

Lead Sponsor: University of Tennessee

Target Recruit Count: 19

Registration Number: NCT01708369

Locations: 🇺🇸
University of Tennessee Health Science Center, Memphis, Tennessee, United States

Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza

Phase 3

Completed

Conditions: Influenza

Interventions: Drug: Nitazoxanide
Drug: Oseltamivir
Drug: Placebo Oral Tablet
Drug: Placebo Oral Capsule

First Posted Date: 2012-06-01

Last Posted Date: 2018-03-29

Lead Sponsor: Romark Laboratories L.C.

Target Recruit Count: 1941

Registration Number: NCT01610245

Locations: 🇦🇺
Influence Study SIte, Nedlands, Western Australia, Australia
🇳🇿
Influence Study Site, Christchurch Central, Christchurch, New Zealand

Oseltamivir for Influenza Lower Respiratory Tract Infection in Children Under One

Phase 2

Withdrawn

Conditions: Influenza

Interventions: Drug: Oseltamivir

First Posted Date: 2012-03-07

Last Posted Date: 2013-07-29

Lead Sponsor: University of Oxford

Registration Number: NCT01546935

Locations: 🇹🇭
Queen Sirikit National Institute of Child Health, Bangkok, Thailand
🇹🇭
Faculty of Medicine Siriraj Hospital, Bangkok, Thailand

Time to Oseltamivir Access When Prescribed by Pharmacists Versus Physicians (ACCESS)

Phase 4

Terminated

Conditions: Influenza

Interventions: Drug: Oseltamivir

First Posted Date: 2011-10-20

Last Posted Date: 2013-08-09

Lead Sponsor: Trial Management Group Inc.

Target Recruit Count: 48

Registration Number: NCT01456234

Locations: 🇨🇦
Springbank Medical Centre, London, Ontario, Canada
🇨🇦
London Road Diagnostic Clinic and Medical Centre, Sarnia, Ontario, Canada
🇨🇦
Dr. Anil Gupta, Toronto, Ontario, Canada

and more 12 locations